Abstract

The invention relates to the use of beta-blocking compounds, in particular the antagonist of ?3 adrenoceptor (?3-ARs), for the treatment of immune-tolerance associated with pathological states, such as cancer.

Research Institution

Università degli Studi di Firenze

Numero di pubblicazione

WO2018116227A1

TRL

3

Technologies, Systems, Applications

Biotechnologies, New drugs development